Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

References

• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24:S5–S11. doi:10.1016/S0268-960X(10)70003-5
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Seer.cancer.gov. Cancer stat facts: myeloma; 2022. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed January 8, 2023.
   Google Scholar
• Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043–3051. doi:10.1182/blood-2014-07-552059
   PubMed Web of Science ®Google Scholar
• Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422–431. doi:10.1182/bloodadvances.2019000524
   PubMed Web of Science ®Google Scholar
• Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017;55:190–199. doi:10.1016/j.ctrv.2017.03.010
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337. doi:10.1182/blood-2007-08-107292
   PubMed Web of Science ®Google Scholar
• Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607–4618. doi:10.1158/1078-0432.CCR-15-0200
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RWJ, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–2049. doi:10.1038/leu.2015.123
   PubMed Web of Science ®Google Scholar
• Sun F, Cheng Y, Peng B, et al. Bispecific CAR-T cells targeting both BCMA and CD24: a potentially treatment approach for multiple myeloma. Blood. 2021;138(Supplement 1):2802. doi:10.1182/blood-2021-148543
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.9789
   PubMed Web of Science ®Google Scholar
• Drent E, Groen RWJ, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616–625. doi:10.3324/haematol.2015.137620
   PubMed Web of Science ®Google Scholar
• Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 2017;130(26):2838–2847. doi:10.1182/blood-2017-04-778423
   PubMed Web of Science ®Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746. doi:10.1126/scitranslmed.aau7746
   PubMed Web of Science ®Google Scholar
• Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196–1206. doi:10.1056/NEJMoa2209900
   PubMed Web of Science ®Google Scholar
• Roy Choudhury S, Byrum SD, Alkam D, et al. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clin Epigenetics. 2023;15(1):18. doi:10.1186/s13148-023-01433-9
   PubMed Web of Science ®Google Scholar
• Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy. Nat Med. 2017;23(12):1436–1443. doi:10.1038/nm.4431
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Mayes PA, Acharya C, et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138. doi:10.1182/blood-2013-10-535088
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–2060. doi:10.1158/1078-0432.CCR-12-2422
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Acharya C, An G, et al. April and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236. doi:10.1182/blood-2016-01-691162
   PubMed Web of Science ®Google Scholar
• O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91–98. doi:10.1084/jem.20031330
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF, April and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263–275. doi:10.1016/j.smim.2006.04.006
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19(11):1143–1156. doi:10.1080/14712598.2019.1641196
   PubMed Web of Science ®Google Scholar
• Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and April for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry. 2005;44(6):1919–1931. doi:10.1021/bi048227k
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–795. doi:10.3324/haematol.2016.150896
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Soof CM, Rajkumar SV, et al. Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). Clin Lymphoma Myeloma Leuk. 2019;37(15_suppl):8020.
   Google Scholar
• Sanchez E, Gillespie A, Tang G, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22(13):3383–3397. doi:10.1158/1078-0432.CCR-15-2224
   PubMed Web of Science ®Google Scholar
• Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. doi:10.1158/1541-7786.MCR-19-0582
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653. doi:10.1016/S1470-2045(18)30576-X
   PubMed Web of Science ®Google Scholar
• GSK. GSK provides update on DREAMM-3 phase III trial for blenrep in relapsed/refractory multiple myeloma; 2022. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/. Accessed January 26, 2023.
   Google Scholar
• Administration USFD. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma; 2020. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed January 26, 2023.
   Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Mohan M, Rein LE, Thalambedu N, et al. Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience. Am J Hematol. 2022;97(12):E451–E453. doi:10.1002/ajh.26728
   PubMed Web of Science ®Google Scholar
• Compassionate use individual request program for belantamab mafodotin in multiple myeloma 213304: expanded access program for belantamab mafodotin in patients with relapsed/refractory multiple myeloma who are refractory to a proteasome inhibitor, and an immunomodulatory agent, and an anti-CD38 antibody. Available from: https://navigator.reaganudall.org/expanded-access/expanded-access-request-program-belantamab-mafodotin-gsk2857916-multiple-myeloma. Accessed April 10, 2023.
   Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1
   PubMed Web of Science ®Google Scholar
• Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discovery. 2021;2(5):423–433. doi:10.1158/2643-3230.BCD-21-0028
   PubMedGoogle Scholar
• Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222–2232. doi:10.1158/1535-7163.MCT-12-0087
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219. doi:10.1056/NEJMoa1506348
   PubMed Web of Science ®Google Scholar
• Watkins-Yoon J, Guzman W, Oliphant A, et al. CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma. Blood. 2019;134(Supplement_1):3182. doi:10.1182/blood-2019-128749
   Google Scholar
• Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2019;1(1):86–98. doi:10.1038/s43018-019-0004-z
   PubMedGoogle Scholar
• Gantke T, Reusch U, Kellner C, et al. AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma. J Clin Oncol. 2017;35(15_suppl):8045.
   Google Scholar
• Chen D, Zou J, Zong Y, Meng H, An G, Yang L. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacol Immunotoxicol. 2016;38(3):175–183. doi:10.3109/08923973.2016.1153110
   PubMed Web of Science ®Google Scholar
• Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific T-cell–redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555–1564. doi:10.1158/1535-7163.MCT-18-1216
   PubMed Web of Science ®Google Scholar
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–2244. doi:10.1056/NEJMoa2204591
   PubMed Web of Science ®Google Scholar
• Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103–119. doi:10.1016/j.pharmthera.2019.04.006
   PubMed Web of Science ®Google Scholar
• FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed January 29, 2023.
   Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi:10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022;77(3):304–311. doi:10.1136/thoraxjnl-2021-217260
   PubMed Web of Science ®Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023. doi:10.1182/bloodadvances.2022009435
   PubMed Web of Science ®Google Scholar
• Guido Lancman KP, Rodriguez C, Richter J, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper163733.html. Accessed April 10, 2023.
   Google Scholar
• MagnetisMM-3: study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one PI, One IMiD and one anti-CD38 mAb. Available from: https://clinicaltrials.gov/ct2/show/NCT04649359. Accessed January 29, 2023.
   Google Scholar
• Pfizer’s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy. Accessed January 29, 2023.
   Google Scholar
• Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140(Supplement 1):388–390. doi:10.1182/blood-2022-166494
   PubMedGoogle Scholar
• 159 efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-Cell Maturation Antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper162440.html. Accessed February 25, 2023.
   Google Scholar
• Cooper D, Madduri D, Lentzsch S, et al. Safety and preliminary clinical activity of REGN5458, an anti-Bcma x anti-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Blood. 2019;134(Supplement_1):3176. doi:10.1182/blood-2019-126818
   Google Scholar
• Naresh Bumma JR, Brayer J, Zonder JA, et al. 4555 updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper159969.html. Accessed January 29, 2023.
   Google Scholar
• Regeneron. Linvoseltamab (BCMAXCD3) initial pivotal phase 2 data show clinically meaningful responses in patients with heavily pre-treated multiple myeloma; 2022. Available from: https://investor.regeneron.com/node/27321. Accessed January 29, 2023.
   Google Scholar
• Naresh Bumma JR, Brayer J, Zonder JA, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper159969.html. Accessed April 10, 2023.
   Google Scholar
• ClinicalTrials.gov. A study to assess AMG 701 montherapy, or in combination with pomalidomide, with or without, dexamethasone in subjects with relapsed or refractory multiple myeloma; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03287908. Accessed February 7, 2023.
   Google Scholar
• Harrison SJ, Minnema MC, Lee HC, et al. A Phase 1 First in Human (FIH) study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood. 2020;136(Supplement 1):28–29. doi:10.1182/blood-2020-134063
   Google Scholar
• Wong NB SW, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): results from a phase 1 first-in-human clinical study; 2022.
   Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement_1):143. doi:10.1182/blood-2019-122895
   Google Scholar
• ClinicalTrials.gov. Study of CC-93269, a BCMA x CD3 T cell engaging antibody, in participants with relapsed and refractory multiple myeloma; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03486067. Accessed February 8, 2023.
   Google Scholar
• ClinicalTrials.gov. A study of TNB-383B in participants with relapsed or refractory multiple myeloma; 2019.
   Google Scholar
• Voorhees PM, D’Souza A, Weisel K, et al. A phase 1 first-in-human study of Abbv-383, a BCMA × CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4401–4404. doi:10.1182/blood-2022-167008
   Google Scholar
• D’Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40(31):3576–3586. doi:10.1200/JCO.22.01504
   PubMed Web of Science ®Google Scholar
• Emma Searle HQ, Wong SW, Megala Costa LJ, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of majesTEC-2, a phase1b, multicohort study; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper159711.html. Accessed April 5, 2023.
   Google Scholar
• Lindsay H, Szabo A, Bhatlapenumarthi V, et al. Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8019.
   Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169
   PubMed Web of Science ®Google Scholar
• Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267–2280. doi:10.1200/JCO.2018.77.8084
   PubMed Web of Science ®Google Scholar
• Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. doi:10.1038/mto.2016.15
   PubMed Web of Science ®Google Scholar
• Noaks E, Peticone C, Kotsopoulou E, Bracewell DG. Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Mol Ther Methods Clin Dev. 2021;20:675–687. doi:10.1016/j.omtm.2021.02.002
   PubMed Web of Science ®Google Scholar
• Lukjanov V, Koutná I, Šimara P, Ponce-Soto LA. CAR T-cell production using nonviral approaches. J Immunol Res. 2021;2021:6644685. doi:10.1155/2021/6644685
   PubMed Web of Science ®Google Scholar
• FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma; 2022. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed February 11, 2023.
   Google Scholar
• FDA approves first cell-based gene therapy for adult patients with multiple myeloma; 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma. Accessed February 11, 2023.
   Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–1014. doi:10.1056/NEJMoa2213614
   PubMed Web of Science ®Google Scholar
• Mi J-Q, Zhao W, Jing H, et al. Phase 2, open-label study of ciltacabtagene autoleucel, an anti-BCMA CAR-T cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1): 26-month median follow-up. Blood. 2022;140(Supplement 1):7542–7544. doi:10.1182/blood-2022-159185
   Google Scholar
• Chunrui LM, Di Wang MD, Baijun Fang MD, et al. 3311 updated results of fumanba-1: a phase 1b/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and/or refractory multiple myeloma; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper166465.html. Accessed February 23, 2023.
   Google Scholar
• Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Blood. 2021;138(Supplement 1):548. doi:10.1182/blood-2021-146518
   Web of Science ®Google Scholar
• Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15_suppl):8504.
   Web of Science ®Google Scholar
• Costa LJ, Kumar SK, Atrash S, et al. Results from the first phase 1 clinical study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2022;140(Supplement 1):1360–1362. doi:10.1182/blood-2022-160038
   Google Scholar
• Chen W, Fu C, Fang B, et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4564–4565. doi:10.1182/blood-2022-168610
   Google Scholar
• Mailankody S, Ghosh A, Staehr M, et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I clinical trial. Blood. 2018;132(Supplement 1):959. doi:10.1182/blood-2018-99-119717
   Web of Science ®Google Scholar
• Fernandez de Larrea C, Gonzalez-Calle V, Cabañas V, et al. Results from a pilot study of ARI0002h, an academic BCMA-directed CAR-T cell therapy with fractionated initial infusion and booster dose in patients with relapsed and/or refractory multiple myeloma. Blood. 2021;138(Supplement 1):2837. doi:10.1182/blood-2021-147188
   Google Scholar
• Li C, Wang X, Wu Z, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma: an updated clinical study. Blood. 2022;140(Supplement 1):4573–4574. doi:10.1182/blood-2022-170686
   Google Scholar
• Sperling AS, Nikiforow S, Nadeem O, et al. Phase I study of PHE885, a fully human BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma manufactured in <2 days using the T-charge TM platform. Blood. 2021;138(Supplement 1):3864.
   Google Scholar
• Qu X, An G, Sui W, et al. Updated phase 1 results of C-CAR088, an anti-BCMA CAR T-cell therapy in relapsed or refractory multiple myeloma. Blood. 2021;138(Supplement 1):1830. doi:10.1182/blood-2021-150037
   PubMedGoogle Scholar
• T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple MyelomaClinically relevant abstract; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper159156.html. Accessed February 26, 2023.
   Google Scholar
• Korst CLBM, Bruins WSC, Cosovic M, et al. Preclinical activity of allogeneic CS1-specific CAR T-cells (UCARTCS1) in multiple myeloma. Blood. 2022;140(Supplement 1):4215–4216. doi:10.1182/blood-2022-157950
   Google Scholar
• ClinicalTrials.gov. Study of bb2121 in multiple myeloma; 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02658929. Accessed February 11, 2023.
   Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309–1318. doi:10.1182/bloodadvances.2021005913
   PubMed Web of Science ®Google Scholar
• Zhao W-H, Liu J, Wang B-Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141. doi:10.1186/s13045-018-0681-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. LCAR-B38M cells in treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2); 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03090659. Accessed February 11, 2023.
   Google Scholar
• Summary basis for regulatory action – carvykti; 2022. Available from: https://www.fda.gov/media/156999/download. Accessed February 11, 2023.
   Google Scholar
• Zhao W-H, Wang B-Y, Chen L-J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a Phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86. doi:10.1186/s13045-022-01301-8
   PubMed Web of Science ®Google Scholar
• Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. doi:10.1038/s41408-022-00629-1
   PubMed Web of Science ®Google Scholar
• Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099–2103. doi:10.1038/s41591-021-01564-7
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi:10.1016/S0140-6736(21)00933-8
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–1274. doi:10.1200/JCO.22.00842
   PubMed Web of Science ®Google Scholar
• Mi JQ, Zhao W, Jing H, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275–1284. doi: 10.1200/JCO.22.00690
   Google Scholar
• ClinicalTrials.gov. A study of LCAR-B38M CAR-T cells, a Chimeric Antigen Receptor T-cell (CAR-T) therapy directed against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1); 2018. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03758417. Accessed February 12, 2023.
   Google Scholar
• Alqazaqi R, Schinke C, Thanendrarajan S, et al. Geographic and racial disparities in access to chimeric antigen receptor–T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw Open. 2022;5(8):e2228877–e2228877. doi:10.1001/jamanetworkopen.2022.28877
   PubMed Web of Science ®Google Scholar
• Faris Jamal Abu Za’nouneh OA, Schinke C, Thanendrarajan S, et al. Variability of definition of high-risk multiple myeloma in phase III clinical trials; 2022. Available from: https://ash.confex.com/ash/2022/webprogram/Paper158188.html. Accessed April 05, 2023.
   Google Scholar
• Leblay N, Maity R, Barakat E, et al. Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood. 2020;136:11–12.
   PubMed Web of Science ®Google Scholar
• Swamydas M, Murphy EV, Ignatz-Hoover JJ, Malek E, Driscoll JJ. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15(1):17. doi:10.1186/s13045-022-01234-2
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape–driven relapse in multiple myeloma. Blood Cancer Discovery. 2020;1(2):146–154. doi:10.1158/2643-3230.BCD-20-0020
   PubMedGoogle Scholar
• Reiser J, Mathavan K, Mahmood S, et al. Dual chimeric antigen receptor approach combining novel tumor targeting strategies circumvents antigen escape in multiple myeloma. Blood. 2021;138(Supplement 1):1718. doi:10.1182/blood-2021-154025
   Google Scholar
• Gazeau N, Beauvais D, Yakoub-Agha I, et al. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv. 2021;5(15):3016–3020. doi:10.1182/bloodadvances.2021004176
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–9551. doi:10.1073/pnas.1819745116
   PubMed Web of Science ®Google Scholar
• Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422–429. doi:10.1038/s41591-022-02182-7
   PubMedGoogle Scholar
• Cao Z, Yang C, Wang Y, et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. Blood. 2022;140(Supplement 1):7378. doi:10.1182/blood-2022-159289
   Google Scholar
• Motais B, Charvátová S, Hrdinka M, Hájek R, Bago JR. Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and γ-secretase inhibitors. Blood. 2022;140(Supplement 1):12683–12684. doi:10.1182/blood-2022-166167
   Google Scholar